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ABSTRACT	18	
Phage	therapy	is	attracting	growing	interest	among	clinicians	as	antibiotic	resistance	19	
continues	 becoming	 harder	 to	 control.	 However,	 clinical	 trials	 and	 animal	 model	20	
studies	on	bacteriophage	treatment	are	still	scarce	and	results	on	the	efficacy	vary.	21	
Recent	research	suggests	that	using	traditional	antimicrobials	in	concert	with	phage	22	
could	have	desirable	synergistic	effects	that	hinder	the	evolution	of	resistance.	Here,	23	
we	present	a	novel	insect	gut	model	to	study	phage-antibiotic	interaction	in	a	system	24	
where	 antibiotic	 resistance	 initially	 exists	 in	 very	 low	 frequency	 and	 phage	25	
specifically	 targets	 the	 resistance	 bearing	 cells.	We	 demonstrate	 that	while	 phage	26	
therapy	could	not	reduce	the	frequency	of	target	bacteria	 in	the	population	during	27	
positive	 selection	 by	 antibiotics,	 it	 alleviated	 the	 antibiotic	 induced	 blooming	 by	28	
lowering	 the	 overall	 load	 of	 resistant	 cells.	The	 highly	 structured	 gut	 environment	29	
had	pharmacokinetic	effects	on	both	phage	and	antibiotic	dynamics	compared	to	in	30	
vitro:	 antibiotics	 did	 not	 reduce	 the	 overall	 amount	 of	 bacteria,	 demonstrating	 a	31	
simple	 turnover	 of	 gut	 flora	 from	 non-resistant	 to	 resistant	 population	 with	 little	32	
cost.	 The	 results	 imply	 moderate	 potential	 for	 using	 phage	 as	 an	 aid	 to	 target	33	
antibiotic	resistant	gut	infections,	and	question	the	usefulness	of	in	vitro	inferences.			34	
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INTRODUCTION	41	
Problems	arising	 from	antibiotic	 resistant	 infections	are	 set	 to	 increase	worldwide.	42	
As	a	consequence,	bacteriophages	(bacteria-specific	viruses)	have	started	to	attract	43	
serious	 consideration	 as	 antimicrobial	 agents	 after	 this	 approach	 was	 largely	44	
forgotten	 for	 decades	 in	 the	 Western	 world	 [1,	 2].	 However,	 their	 efficacy	 as	45	
therapeutic	 agents	 remains	 controversial	 [3].	 Some	 of	 the	 in	 vivo	 work	 promises	46	
therapeutic	potential	in	insect	[4],	mouse	[5],	and	human	infections	[6],	and	in	vitro	47	
experiments	show	overwhelming	evidence	of	phages	controlling	bacterial	population	48	
sizes	 without	 adverse	 effects	 on	 non-target	 bacteria	 [7].	 Despite	 this,	 the	 few	49	
existing	modern	and	properly	controlled	medical	 trials	report	varying	success	 [3,	6,	50	
8].	Key	 limitations	of	phage	therapy	 include	high	specificity,	ease	at	which	bacteria	51	
can	evolve	resistance,	and	localised	activity	in	the	body.		52	
	It	has	been	argued	that	phages	may	be	of	particular	therapeutic	value	when	53	
combined	with	antibiotics,	by	 constraining	 the	emergence	and	 spread	of	antibiotic	54	
resistance	 [9].	A	 good	example	of	 recent	 success	 in	 combination	 treatment	 comes	55	
from	a	difficult	chronic	Pseudomonas	aeruginosa	infection	in	human	aortic	graft	[10].		56	
Theoretically,	 phages	 may	 limit	 antibiotic	 resistance	 during	 treatment	 because	 of	57	
reduction	 in	population	size	and	synergistic	costs	of	 resistance	 [9].	Moreover,	with	58	
cases	 where	 antibiotic	 resistance	 is	 carried	 on	 plasmids,	 phages	 can	 be	 used	 to	59	
directly	target	the	plasmid	carrying	cells	[11].	However,	this	latter	approach	has	only	60	
been	 investigated	 in	 vitro	 [11,	12],	which	 ignores	a	plethora	of	 selection	pressures	61	
towards	both	the	host	bacteria	and	the	phage,	such	as	host	immune	system,	spatial	62	
structures	within	 the	tissues,	nutrient	availability,	and	presence	of	native	microbial	63	
flora	[13].	64	
Here,	we	 studied	 the	effects	of	 antibiotic	 and	phage	 treatment	 to	bacterial	65	
load	 and	 frequency	 of	 resistance	 in	 a	 gnotobiotic	 insect	 gut	model	 system,	where	66	
phages	 target	 the	 bacteria	 harbouring	 antibiotic	 resistance	 plasmids.	We	 compare	67	
these	 findings	 to	 in	 vitro	 context	 to	 assess	 the	 usefulness	 of	 inferring	 in	 vivo	68	
dynamics	 from	 in	 vitro	 studies.	A	 full	 factorial	 setup	of	antibiotics	and	phage	were	69	
orally	 administered	 to	 cabbage	 looper	 (Trichoplusia	 ni)	 larvae	 harbouring	70	
Enterobacter	cloacae	gut	bacteria	and	a	low	initial	frequency	of	antibiotic	resistance	71	
plasmid.	We	show	that	targeting	the	tetracycline	resistant	cells	with	phage	could	not	72	
prevent	the	increase	in	resistance	frequency	in	the	presence	of	antibiotics.	However,	73	
phage	 reduced	 the	 bacterial	 population	 size	 when	 plasmid	 was	 driven	 to	 high	74	
frequency	with	antibiotic	selection.	75	
MATERIALS	AND	METHODS	76	
Although	 it’s	 been	 argued	 that	 Lepidopterans	 lack	 a	 resident	 microbiome	 [14],	77	
Enterobacter	cloacae	 forms	a	persistent	gut	association	with	Lepidopteran	larvae	78	 [15]	after	oral	inoculation.	The	strain	was	isolated	from	P.	xylostella	in	the	insectary	79	
of	 University	 of	 Oxford.	Two	 spontaneous	 antibiotic	 resistant	mutants,	 ANC	 C2	80	 (rifR)	 and	 11.1B	 	 (strepR	 +	 nalR)	 were	 used	 in	 this	 experiment.	 The	 IncP-type	81	 plasmid	RP4,	coding	 for	 tetracycline	resistance,	 is	usually	conjugative	[16],	and	82	 the	 lytic,	 plasmid	 dependent	 tectivirus	 PRD1	 specifically	 infects	 RP4-bearing	83	 cells	by	recognising	the	bacterial	sex-apparatus	[17].	However,	in	this	system	the	84	 plasmid	 is	essentially	non-conjugative	and	 functions	as	a	carrier	of	 tetracycline	85	
resistance	 and	 phage	 receptor	 genes.	 The	 mechanistic	 basis	 for	 low	 RP4	86	
conjugation	 in	 these	 E.	 cloacae	 strains	 is	 unclear.	 Given	 that	 the	 phage	 remains	87	
infective,	 it	 could	 be	 that	 ANC	 C2	 rifampicin-resistant	 mutant	 was	 an	 impotent	88	
recipient	 for	 the	 plasmid	 rather	 than	 that	 11.1B(RP4)	 lacked	 the	 ability	 to	 express	89	
pili.	 Although	 rifampicin	 resistance	 mutations	 are	 most	 often	 polymerase	 related,	90	
known	 mechanisms	 in	 Enterobacteriaceae	 include	 elongated	 or	 abundant	 outer	91	
membrane	LPS-chains	 [18]	 that	 could	 theoretically	 interfere	with	 conjugation	 (but,	92	
see:	[19]).	93	
	 The	 in	vitro	experiment	used	200	μl	cultures	on	a	96-well	plate	with	LB	and	94	
0.1%	starting	 frequency	of	plasmid.	24	replicate	populations	were	subjected	to	 full	95	
factorial	antibiotic	(AB)	and	phage	(P)	treatment:	AB–	P–,	AB–	P+,	AB+	P–,	and	AB+	96	
P+,	 respectively.	 The	 antibiotic	 treatments	 were	 set	 to	 12	 μg/mL	 tetracycline	 and	97	
phage	 starting	 density	 to	 5	 ×	 107	 phage	 particles.	 The	 growth	 in	 optical	 density	98	
(600nm)	was	recorded	at	24	h	with	a	spectrophotometer	in	30°C.	Plasmid	frequency	99	
and	transconjugants	were	sampled	from	a	subset	 (N=44)	of	populations	at	24	h	by	100	
selective	plating.			101	
	 The	 T.ni	 were	maintained	 as	 follows:	 The	 adults,	 fed	with	 100mM	 sucrose	102	
solution,	were	let	to	mate	and	lay	eggs	on	paper	strips	in	flight	chambers.	The	eggs	103	
were	 placed	 in	 autoclaved,	 single-filter	 vented,	 305	 x	 203	 x	 100mm	 Genesis™	104	
containers	for	surgical	instruments	to	maintain	sterile	conditions	while	allowing	gas	105	
exchange.	Hatched	larvae	were	let	to	feed	on	Hoffman	diet	(288	g	wheatgerm,	132	g	106	
caesin,	117	g	sucrose,	70	g	agar,	57	g	dried	brewers	yeast,	37.5	g	Wesson’s	salts,	6	g	107	
sorbic	acid,	3.75	g	cholesterol,	3.75	g	methyl-4-hydroxybenzoate	and	2	g	Vanderzant	108	
vitamin	mixture	in	2750	ml	water)	[20].	The	liquid	medium	was	poured	into	a	sterile	109	
steel	mould	and	solidified	to	diet	cubes	with	approximately	25mm	edges.	The	cubes	110	
were	 placed	 on	 Petri	 dish	 covers	 inside	 the	 containers.	 All	 rearing	 and	 in	 vivo	111	
bacterial	work	was	 carried	out	 in	25	 °C.	 For	population	maintenance,	50-60	pupae	112	
were	removed	from	their	cocoons	per	flight	chamber	and	let	to	emerge	and	mate	to	113	
start	a	new	generation	of	hosts.		114	
	 For	 inoculating	 the	 larval	 gut	 with	 E.	 cloacae,	 clones	 ANC	 C2	 and	 11.1B	115	
bearing	RP4	were	grown	over	night	in	LB	(30	°C,	180	rpm	shaking),	the	latter	diluted	116	
1:10	with	0.85	%	NaCl,	and	then	mixed	together	in	a	50:1	ratio.	The	frequency	of	the	117	
plasmid	bearing	cells	was	counted	by	dilution	plating	as	0.072%	and	bacterial	density	118	
approximately	1.2	×	108	CFU.	Diet	cubes	were	dipped	in	this	solution,	dried	for	5	min,	119	
and	3rd	instar	larvae	were	allowed	to	feed	on	this	bacterial	diet	for	30	h.	The	larvae	120	
were	 then	 subjected	 to	 the	 AB–	 P–,	 AB–	 P+,	 AB+	 P–,	 and	 AB+	 P+	 treatments.	121	
Tetracycline	 (200	μg/mL	 final	 concentration)	was	 added	directly	 to	 the	 autoclaved	122	
diet	mix	and	30	μl	of	1010	pfu/mL	filtered	phage	lysate	was	pipetted	onto	each	face	123	
of	 the	 phage	 treatment	 diet	 cubes.	 The	 experiment	 was	 carried	 out	 in	 two	124	
independent	 batches	 (final	 N=156	 larvae).	 After	 96	 h,	 the	 larvae	 were	 surface	125	
sterilised	 with	 70%	 alcohol	 and	 homogenised	 in	 500	 μl	 0.85%	 NaCl	 with	 Qiagen	126	
Tissuelyser	 II™.	 The	 homogenate	 was	 serially	 diluted	 and	 plated	 on	 12	 μg/mL	127	
tetracycline,	12	μg/mL	tetracycline	+	100	μg/mL	rifampicin,	and	LB	plates	to	calculate	128	
the	frequencies	of	plasmid	carriers,	transconjugants,	and	total	density	of	bacteria.	24	129	
bacterial	 clones	 from	 the	 phage	 treatment	 serial	 dilutions	 on	 tetracycline	 were	130	
tested	for	resistance	against	the	ancestral	phage	with	a	phage	plaque	overlay	assay.	131	
Phage	 survival	 in	 the	 gut	 was	 confirmed	 by	 overlaying	 homogenised	 larval	 faecal	132	
samples	on	ancestral	11.1B(RP4)	lawn	on	soft	agar	and	observing	plaque	formation	133	
(N=24).			134	
	 Treatment	 effects	 on	 densities	 and	 frequencies	 in	 both	 experiments	 were	135	
analysed	 with	 SPSS	 statistics	 21.0	 with	 antibiotics,	 phage,	 and	 antibiotics*phage	136	
interaction	 in	ANOVA-GLM	model.	 Post-hoc	multiple	 comparisons	were	Bonferroni	137	
corrected.		138	
RESULTS	 	139	
In	vitro,	antibiotics	and	phage	had	synergistic	effects	on	the	total	density	of	bacteria	140	
at	24h	(AB:	F1,	96=3528.0,	p<0.001,	P:	F1,	96=73.7,	p<0.001,	AB*P:	F1,	96=97.0,	p<0.001).	141	
Multiple	 comparisons	 showed	 that	 there	 was	 no	 phage	 effect	 in	 absence	 of	142	
antibiotics,	but	other	pairwise	differences	were	highly	significant	(p<0.001,	Fig.	1.	a).	143	
Thus,	 single	 treatment	 allowed	 compensatory	 growth	of	 the	non-target	 strain,	 but	144	
this	effect	was	 reduced	 for	 the	plasmid	carriers	 in	 the	presence	of	antibiotics.	The	145	
plasmid	 went	 to	 near	 fixation	 in	 the	 presence	 of	 antibiotics	 (F1,	 147	 44=8864.4,	146	
p<0.001)	regardless	of	the	phage	(P	and	AB*P:	p>0.05).	This	was	contrary	to	previous	147	
studies	with	the	same	plasmid	and	phage	in	E.	coli	 [12].	 	The	increase	in	frequency	148	
was	not	the	result	of	conjugational	transfer,	because	unlike	 in	E.	coli,	RP4	had	very	149	
low	conjugation	rate	in	E.	cloacae:	transconjugants	were	present	in	only	one	of	the	150	
44	sampled	in	vitro	populations	(AB+P-	treatment	at	a	very	low	frequency).	We	also	151	
confirmed	that	the	phage	remained	infective	even	with	low	conjugation.	The	cost	of	152	
plasmid	carriage	in	the	absence	of	antibiotics	manifested	itself	as	complete	plasmid	153	
extinction	 (at	 least	 below	 the	 detection	 threshold	 of	 <67	 cfu/mL)	 in	 all	 sampled	154	
populations	(Fig	1.	b).	This	was	the	case	even	though	RP4	has	been	reported	to	be	of	155	
low	 cost	 and	 rapidly	 evolve	 towards	 no	 cost	 through	 chromosomal	 compensatory	156	
mutations	[21].	 	157	
In	vivo	patterns	of	plasmid	dynamics	were	mainly	similar	to	that	observed	in	158	
vitro,	but	the	effects	smaller.		The	non-targeted	strain	could	fully	compensate	for	the	159	
reduction	in	density	of	the	competing	strain	(AB:	F1,	156=0.1,	p=0.77),	and	phage	had	160	
no	 main	 effect	 on	 total	 bacterial	 load	 (P:	 F1,	 156=3.0,	 p=0.085).	 Phage	 however	161	
lowered	 bacterial	 density	 in	 the	 presence	 of	 antibiotics	 (interaction:	 F1,	 156=6.7,	162	
p=0.011),	demonstrating	that	the	treatment	synergism	was	maintained	in	vivo	(post	163	
hoc	AB+	P–	and	AB+	P+,	p=0.020,	Fig.	2.	a).	Phage-susceptibility	screening	of	evolved	164	
clones	 showed	 no	 emergence	 of	 resistance.	 Plasmid	 increased	 in	 frequency	 in	 all	165	
treatments,	 but	 tetracycline	 selection	 drove	 the	majority	 of	 the	 population	 to	 be	166	
plasmid	carriers	with	no	effects	of	phage	addition	(effects	on	plasmid	frequency,	AB:	167	
F1,	156=845.0,	p<0.001;	P:	F1,	156=0.6,	p=0.43;	AB*P:	F1,	156=0.4,	p=0.55	(Fig.	2.	b).	Thus,	168	
phage	therapy	could	not	restrict	the	spread	of	antibiotic	resistance	in	the	T.	ni	gut.	169	
DISCUSSION	170	
Here,	 we	 investigated	 the	 effect	 of	 plasmid-targeting	 phage	 on	 the	 spread	 of	171	
antibiotic	resistance	plasmid	in	vitro	and	in	an	insect	gut	model.		Different	selective	172	
environment	 in	 the	 gut	made	 treatment	 effects	 less	 pronounced	 compared	 to	 the	173	
liquid	culture:	for	example,	the	increased	complexity	in	spatial	structures	may	have	174	
protected	the	plasmid	from	extinction	in	the	absence	of	antibiotics,	and	thus	allowed	175	
more	non-resistant	bacteria	to	coexist	in	the	presence	of	tetracycline.	This	happened	176	
even	though	the	antibiotic	concentration	in	the	diet	was	over	16	times	higher	than	in	177	
the	liquid	culture	and	the	experiment	length	4	times	longer,	allowing	more	time	for	178	
potential	 fixation	 and/or	 extinction	 to	 happen.	 Phage	 driven	 reduction	 in	 the	179	
bacterial	population	size	in	the	presence	of	tetracycline	was	also	more	moderate	 in	180	
vivo,	 but	 it	 is	 also	 notable	 that	 no	 detectable	 phage	 resistance	 emerged	 in	 the	181	
sampled	 populations.	 Surprisingly,	 antibiotics	 did	 not	 reduce	 the	 overall	 bacterial	182	
density	 in	the	gut,	but	rather	replaced	non-resistant	cells	with	resistant	ones	while	183	
population	 size	 remained	 the	 same.	 	 In	 other	 words,	 antibiotics	 increased	 the	184	
relative	fitness	of	the	resistant	strain	without	reducing	the	absolute	fitness	[22].	This	185	
was	in	contrast	with	liquid	culture	where	the	plasmid	went	even	closer	to	fixation	in	186	
the	 presence	 of	 antibiotics,	 but	 resulted	 in	 lower	 total	 bacterial	 density,	 which	187	
suggests	 a	 greater	 growth	 cost	 associated	 with	 antibiotic	 resistance	 in	 vitro.	 We	188	
cannot	 attribute	 the	 inversion	 of	 fitness	 effects	 between	 in	 vivo	 and	 in	 vitro	189	
conditions	(increase	in	plasmid	frequency	 in	vivo,	and	extinction	 in	vitro	 in	absence	190	
of	 antibiotics)	 directly	 to	 the	 plasmid,	 because	 it	 could	 also	 be	 due	 to	 unknown	191	
differences	in	the	mutant	strains.	The	result	still	highlights	the	limitations	of	making	192	
inferences	from	test	tube	dynamics.	193	
In	 the	 absence	 of	 antibiotics	 neither	 in	 vitro	 nor	 in	 vivo	 regimes	 showed	 a	194	
phage	effect	on	 the	bacterial	population	 size,	which	was	not	 surprising	because	of	195	
very	 low	 initial	 frequency	 of	 phage-susceptible	 (i.e.	 plasmid	 bearing)	 cells.	 Most	196	
importantly,	when	antibiotic	selection	increased	the	frequency	of	phage-susceptible	197	
cells	 by	 spreading	 antibiotic	 resistance,	 phage	 decreased	 the	 total	 density	 of	198	
bacteria.	This	effect	was	bigger	in	vitro,	but	also	clearly	visible	in	the	insect	gut.	The	199	
gut	 lumen	 is	 a	 favourable	 environment	 for	 bacterial	 biofilm	 formation	 [23],	which	200	
can	 offer	 non-resistant	 cells	 spatial	 protection	 from	 antibiotics	 [24]	 and/or	 from	201	
phage	 [25].	 On	 the	 other	 hand,	 it	 could	 be	 that	 the	 observed	 phage	 efficacy	 to	202	
reduce	bacterial	load	in	vivo	is	partly	due	to	their	known	ability	to	eradicate	biofilms	203	
[26,	27],	which	can	be	important	for	bacterial	persistence	in	the	insect	gut	[23].								204	
	 One	 potential	 epidemiological	 implication	 of	 viable	 phages	 in	 the	 faeces	 is	205	
that	the	viral	therapeutic	agent	could	restrict	ongoing	pathogen	transmission	or	be	206	
transmitted	with	the	target	pathogen	[28].	The	model	system	presented	in	this	study	207	
allows	 the	 manipulation	 of	 structure	 and	 connectivity	 of	 the	 population	 of	 the	208	
treated	 organism	 and	 would	 be	 an	 interesting	 future	 endeavour	 towards	209	
epidemiological	 effects	 of	 phage	 therapy.	 Our	 findings	 have	 implications	 for	210	
therapeutic	use	of	phage,	especially	considering	synergistic	evolutionary	effects	with	211	
antibiotics	 [9].	 However,	 antibiotics	 overwhelmed	 the	 selection	 imposed	 by	 the	212	
phages,	 meaning	 that	 the	 relative	 effect	 remained	 rather	 small.	 This	 could	 be	213	
improved	 with	 using	 more	 efficient	 phages	 or	 phage	 cocktails	 in	 a	 way	 that	 can	214	
target	wider	niche	space	 in	vivo	by,	 for	example,	biofilm	specificity	[27].	 It	has	also	215	
been	 shown	 that	 the	 effect	 of	 phage	 on	 plasmid-maintenance	 can	 depend	 on	 the	216	
type	 of	 antibiotics	 that	 are	 used	 [29].	 To	 conclude,	 within-organism	217	
pharmacokinetics	and	the	spatial,	temporal,	and	resource-related	dynamics	are	very	218	
different	 compared	 to	 a	 test	 tube,	 having	 major	 effects	 on	 cost	 of	 resistance,	219	
magnitude	of	 selection,	and	 treatment	efficacy	even	 in	a	highly	 simplified	and	 low	220	
diversity	model	system.	 	221	
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Figure	1.	Dynamics	in	vitro	245	
The	density	of	bacteria	(a),	and	the	frequency	of	plasmid	bearing	cells	(b)	in	246	
liquid	culture	after	a	24	h	factorial	antibiotic	(AB)	and	phage	(P)	treatments.	247	
Error	bars	are	+/–	1	S.E.,	(**)	denotes	p<0.001	difference.	248	
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Figure	2.	Dynamics	in	vivo	252	
The	overall	density	of	bacteria	(a)	and	the	frequency	of	plasmid	bearing	cells	253	
(b)	 in	 the	 larval	 guts	 after	 a	 96	 h	 factorial	 antibiotic	 (AB)	 and	 phage	 (P)	254	
treatments.		Error	bars	are	+/–	1	S.E.	(*)	and	(**)	denote	p<0.05	and	p<0.001	255	
differences,	respectively.	256	
	257	
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